What is Geron?
Geron operates at the intersection of biotechnology and oncology, focusing on the development of first-in-class telomerase inhibitors. Its primary asset, imetelstat, is currently undergoing intensive evaluation in two pivotal Phase 3 clinical trials: IMerge, targeting lower-risk myelodysplastic syndromes, and IMpactMF, addressing refractory myelofibrosis. As a late-stage entity, Geron occupies a critical position in the biopharmaceutical landscape, aiming to address significant unmet medical needs in hematologic malignancies through targeted therapeutic intervention.
How much funding has Geron raised?
Geron has raised a total of $466M across 3 funding rounds:
Stock Offering
$16M
Debt
$75M
Debt
$375M
Stock Issuance/Offering (1996): $16M, investors not publicly disclosed
Debt (2020): $75M led by Hercules Capital and Silicon Valley Bank
Debt (2024): $375M supported by Royalty Pharma
Key Investors in Geron
Royalty Pharma
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation, collaborating with academic institutions and biotech companies to co-fund late-stage clinical trials.
Hercules Capital
Hercules Capital is a specialty finance firm providing senior secured venture growth loans to high-growth, innovative companies across the life sciences and technology sectors.
Silicon Valley Bank
Silicon Valley Bank provides specialized commercial and private banking, asset management, and investment services tailored to the needs of the innovation economy.
What's next for Geron?
With the recent infusion of capital, Geron is well-positioned to accelerate its clinical milestones and prepare for potential commercialization. The strategic focus remains on the successful execution of the IMerge and IMpactMF trials, which are essential for regulatory approval and market entry. Investors and stakeholders are closely monitoring the company's ability to translate its clinical data into a viable commercial product, a move that would solidify its standing as a leader in the telomerase inhibition space. The current funding structure provides the necessary runway to navigate the complexities of late-stage clinical development and the subsequent transition into a commercial-stage enterprise.
See full Geron company page
